Pharmaceutical-grade, Radiopaque Perflubron
Intended Use: Liquivent is intended to be used as an aid in removing debris, secretions, and foreign matter from the lungs via bronchoalveolar lavage (BAL).
Intended Use: Liquivent is intended to be used as an aid in removing debris, secretions, and foreign matter from the lungs via bronchoalveolar lavage (BAL).
CE Marked.
USA: For Research Use Only.
OriGen sells direct and works with a network of global distributors. For availability in your country, please contact us below.
ML28.R03
Liquivent is for research use only in the USA. The CE-approved intended use is as an aid in removing debris, secretions, and foreign matter from the lungs via bronchoalveolar lavage (BAL).
While it does evaporate, there will be residual Perflurobron left in the lungs that should be suctioned out. When used for bronchial lavage, it is instilled into the lungs and suctioned back out.
10-20ml/kg for bronchial lavage.
Please contact customer service at 512-474-7878, submit a quote request form, or email info@origen.com for pricing and availability.
3 years
Please report it as soon as possible. Contact the OriGen head office or your sales representative. Please retain the product and its packaging as this will help us in our investigation and findings. All complaints will receive a written or oral response acknowledging receipt of the product and initial findings.
An IFU and CoA will be in your original shipment box. If these items are misplaced, you can access the IFU and CoA for your OriGen products through the Client Login. If you do not have a current login, you will need to register for an account through that page.
1. Reickert C, Praniko_ T, Overbeck M, Kazerooni E, Massey K, Bartlett R, Hirschl R. “The Pulmonary And Systemic Distribution And Elimination Of Perflubron From Adult Patients Treated With Partial Liquid Ventilation” Chest. 2001 Feb; 119(2):515-522.
2. Steinhorn DM, Leach CL, Fuhrman BP, Holm BA. “Partial Liquid Ventilation Enhances Surfactant Phospholipid Production.” Critical Care Med. 1996 Jul; 24(7):1252-6.
3. Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1043-54. doi: 10.3109/10731199409138801. PMID: 7849908.
4. Broaddus, V. C., Ernst, J. D., King, T. E., Lazarus, S. C., Sarmiento, K. F., Schnapp, L. M., Stapleton, R. D., & Gotway, M. B. (2022). Murray & Nadel’s textbook of Respiratory Medicine (7th ed.). Elsevier.
5. Farnham, RRT, Bill. “An American Perspective.” RT Magazine, 7 Feb. 2007, https://rtmagazine.com/disorders-diseases/critical-care/ards/an-american-perspective/.
6. Patankar, Nikhil; Al-Ibrahim, Omar 716, Critical Care Medicine: December 2015 – Volume 43 – Issue 12 – p 180. doi: 10.1097/01.ccm.0000474544.58195.50.
7. Haeberle H. A., Nesti F., Dieterich H.-J., Gatalica Z., Garofalo R. P. (2002). Perflubron Reduces Lung Inflammation in Respiratory Syncytial Virus Infection by Inhibiting Chemokine Expression and Nuclear Factor-˜B Activation. Am. J. Respir. Crit. Care Med. 165, 1433–1438. Doi:10.1164/rccm.2109077.
Liquivent® is a registered trademark of OriGen Biomedical, Inc.
Learn more about the custom product development process by clicking below.